The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic alterations driving breast cancer (BC) metastases and their relationship with the subtype switch in the GEICAM ConvertHER study.
 
Joan Albanell
No Relationships to Disclose
 
Abel Gonzalez
No Relationships to Disclose
 
Ana M. Gonzalez-Angulo
No Relationships to Disclose
 
Agda Karina Eterovic
No Relationships to Disclose
 
Eduardo Martinez-De Duenas
Consulting or Advisory Role - Roche Pharma AG
 
Xiaofeng Zheng
No Relationships to Disclose
 
Angel Guerrero
No Relationships to Disclose
 
Shuying Liu
No Relationships to Disclose
 
Ramon Pérez-Carrión
No Relationships to Disclose
 
Ken Chen
No Relationships to Disclose
 
Jose Ignacio Chacon
No Relationships to Disclose
 
Gordon B. Mills
Stock and Other Ownership Interests - Catena; Immunome; Myriad Genetics; PTV Sciences; Spindletop Ventures
Honoraria - Allostery; AstraZeneca; Immunome; Isis Pharmaceuticals; Lilly; Novartis; Nuevolution; Symphony Evolution
Consulting or Advisory Role - Adventis Health; Allostery; AstraZeneca; Catena; Critical Outcome Technologies; Isis Pharmaceuticals; Lilly; MedImmune; Millennium; Novartis; Nuevolution; Precision Medicine Research Associates, LLC; Provista Diagnostics; SignalChem; Symphony Evolution; Tarveda Therapeutics; Tau Therapeutics
Research Funding - Adelson Medical Research Foundation; AstraZeneca; Breast Cancer Research Foundation; Critical Outcome Technologies; Illumina; Karus Therapeutics; Komipharm; Millennium; NanoString Technologies
Patents, Royalties, Other Intellectual Property - HRD assay to Myriad Genetics
Travel, Accommodations, Expenses - Allostery; AstraZeneca; Immunome; Isis Pharmaceuticals; Lilly; MedImmune; Novartis; Pfizer; Symphony Evolution
 
Silvia Antolín Novoa
No Relationships to Disclose
 
Isabel Blancas
No Relationships to Disclose
 
Maria Sanchez-Arago
No Relationships to Disclose
 
Eva Maria Carrasco
Stock and Other Ownership Interests - Lilly
Consulting or Advisory Role - Bristol-Myers Squibb (I); Celgene (I); Novartis (I); Roche Pharma AG (I)
Speakers' Bureau - Bristol-Myers Squibb (I); Celgene (I); Novartis (I); Roche Pharma AG (I)
Research Funding - AstraZeneca Spain (Inst); AstraZeneca Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genomic Health (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - PAM 50 taxane predictor
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); Celgene (I); Novartis (I); Roche
 
Rosalia Caballero
No Relationships to Disclose
 
Federico Rojo
No Relationships to Disclose
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks
 
Ana Lluch Hernandez
Speakers' Bureau - Novartis; Pfizer; Roche